Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT07438626
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:19.209272+00:00
Published At
2026-03-02T00:00:00+00:00
Record Updated At
2026-03-02
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Phase II", "Sacituzumab", "Tirumotecan", "SMARCB1-deficient Renal Medullary Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-03-02"
protocolSection.identificationModule.nctId
"NCT07438626"
protocolSection.identificationModule.officialTitle
"Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma"
protocolSection.statusModule.overallStatus
"NOT_YET_RECRUITING"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Phase II (protocolSection.conditionsModule.conditions)
  • Sacituzumab (protocolSection.conditionsModule.conditions)
  • Tirumotecan (protocolSection.conditionsModule.conditions)
  • SMARCB1-deficient Renal Medullary Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.